# Thymmune Therapeutics

> Thymmune Therapeutics is a Cambridge, Massachusetts biotech turning induced pluripotent stem cells into off-the-shelf thymic cells that can rebuild the thymus, the small organ behind the breastbone that trains the immune system and fades with age. Founded in 2019 by physician-scientist Stan Wang, the company pairs a machine-learning-guided manufacturing platform with a lead program, THY-100, aimed at congenital athymia. After $7M in seed funding, a Series A, and a $37M ARPA-H award, it was acquired by United Therapeutics in July 2026 in a deal worth up to $300 million.

- **Founded:** 2019
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Stan Wang (CEO & Founder)
- **Team size:** ~25 employees
- **Products:** THY-100, iPSC Thymic Cell Engineering Platform, Thymus Rejuvenation Program
- **Notable:** Received what was reported as ARPA-H's first industry grant (up to $37M) in 2023., Demonstrated in animal studies that THY-100 can form neo-thymus tissue supporting T-cell development., Built a scalable, machine-learning-guided iPSC-to-thymic-cell manufacturing platform.

## Products & services

- **THY-100** — Lead program: an iPSC-derived thymic cell therapy targeting congenital athymia, an ultra-rare condition in which infants are born without a functional thymus. In animal studies it formed neo-thymus tissue capable of supporting T-cell development.
- **iPSC Thymic Cell Engineering Platform** — A machine-learning-driven manufacturing platform that converts human induced pluripotent stem cells into thymic epithelial and supporting cells at scale, designed for off-the-shelf therapeutic use.
- **Thymus Rejuvenation Program** — ARPA-H-funded research using human iPSC-derived thymic epithelial cells to restore T-cell development and slow immunologic aging, with applications in transplant tolerance and autoimmune disease.

## Achievements

- Received what was reported as ARPA-H's first industry grant (up to $37M) in 2023.
- Demonstrated in animal studies that THY-100 can form neo-thymus tissue supporting T-cell development.
- Built a scalable, machine-learning-guided iPSC-to-thymic-cell manufacturing platform.
- Acquired by United Therapeutics in July 2026 in a deal worth up to $300 million.
- Grew from a 2019 spinout to a ~25-person company with $44M+ in disclosed funding before acquisition.

## Latest updates

- **2026-07** — United Therapeutics acquired Thymmune Therapeutics for $140M upfront cash plus up to $160M in milestone earn-outs (up to $300M total).
- **2023-09** — Received up to $37M from ARPA-H for the Thymus Rejuvenation program.
- **2023-03** — Raised $7M seed round led by Pillar VC to build its thymic cell therapy platform.

## Links

- Website: https://thymmune.com
- LinkedIn: https://www.linkedin.com/company/thymmune

---

Profile page: https://yespress.io/thymmune-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-21